US2021164011A1PendingUtilityA1
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
Est. expiryApr 2, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Volker SchellenbergerJoshua SilvermanChia-Wei WangBenjamin SpinkWillem P. C. StemmerNathan Geething
C07K 14/8125C07K 14/7155C07K 2317/622C07K 14/70521C07K 16/2809C07K 2317/31C12N 15/625C07K 2317/94C12P 21/02A61P 11/08C07K 16/2863A61P 11/00C07K 2319/74A61P 1/16C07K 14/00C07K 16/18C07K 16/241C07K 16/244C07K 2317/569C07K 16/40A61K 38/00C07K 2317/92C07K 2319/31C07K 16/32C07K 2319/70C07K 16/2878
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
Claims
exact text as granted — not AI-modified1 . An isolated binding fusion protein comprising a first extended recombinant polypeptide (XTEN) comprising at least 36 amino acid residues and a first targeting moiety with specific binding affinity to a first target, wherein said fusion protein exhibits a terminal half-life that is longer than about 72 hours when administered to a subject.
2 - 28 . (canceled)Join the waitlist — get patent alerts
Track US2021164011A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.